Oligometastatic renal cell carcinoma (OM-RCC) refers to patients who have limited (typically up to 5) metastatic lesions. Although management principles may overlap, OM-RCC is distinguishable from oligoprogressive RCC, which describes progression of disease to a limited number of sites while receiving systemic therapy. Cytoreductive nephrectomy and metastasectomy are common surgical considerations in OM-RCC, and indications are discussed in this review. It is evident that stereotactic ablative radiotherapy is effective in RCC and is being applied increasingly in the oligometastatic setting. Finally, we will review advances in systemic therapy and the role of active surveillance before the initiation of systemic therapy.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2023 May [Epub]
Shawn Dason, Kristine Lacuna, Raquibul Hannan, Eric Singer, Karie Runcie
Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY., Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX.